EMEA-000052-PIP01-07-M03
Key facts
| Invented name |
Caprelsa
|
| Active substance |
Vandetanib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0285/2013
|
| PIP number |
EMEA-000052-PIP01-07-M03
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of medullary thyroid carcinoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AstraZeneca AB (Sweden)
E-mail: paediatrics@astrazeneca.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000052-PIP01-07-M03
|
| Compliance opinion date |
20/06/2014
|
| Compliance outcome |
positive
|